ClearPoint Neuro, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $275.7M
- Price
- $8.60
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.04%
- Volume
- 946.0K
About
ClearPoint Neuro, Inc. is a medical technology firm primarily operating within the United States. The company specializes in developing and commercializing sophisticated systems that facilitate minimally invasive brain surgeries, guided by real-time magnetic resonance imaging (MRI) during the procedure. Among its core offerings is the ClearPoint system, designed for the precise placement of deep brain stimulation electrodes, biopsy needles, and for the controlled infusion of medications and laser catheters directly into the brain. It also provides the ClearPoint Neuro Navigation System, which is specifically engineered for MRI suite environments. ClearPoint Neuro maintains strategic partnerships and licensing agreements with prominent institutions and companies, including Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and the University of California, San Francisco. Initially established in 1998 and headquartered in Solana Beach, California, the company operated as MRI Interventions, Inc. before rebranding to ClearPoint Neuro, Inc. in February 2020.
Quick stats
Shares outstanding32.1M
Computed float28.3M
Float / shares88.3%
Cash runway (months)15.9
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001285550
AI Summary
AI-generated1/45
majormixedearnings
ClearPoint Neuro Reports Third Quarter 2026 Results
ClearPoint Neuro reported Q3 2026 revenue of $12.1 million, up 36% year-over-year, boosted by the IRRAflow portfolio acquired with IRRAS in late 2025.
Neurosurgery navigation and therapy revenue grew 59% to $5.4 million and capital equipment/software hit a record $1.7 million, while biologics and drug delivery returned to double-digit growth at $4.9 million.
Profitability remains the weak spot: gross margin fell to 58% from 63%, operating loss widened to $6.3 million, and net loss was $7.5 million ($0.24 per share) as operating expenses grew 23%.
Management guided 2026 revenue to $48-50 million, and the company ended the quarter with $46.2 million in cash after raising $22.0 million via an at-the-market equity program that offset $20.1 million of nine-month operating cash burn.
Red flags
- gross margin declined 5 points to 58% on lab overhead and acquisition amortization
- net loss widened to $7.5M from $5.9M year-over-year
- operating cash burn of $20.1M in nine months funded by $22.0M ATM equity issuance (dilution: shares outstanding up ~9% since year-end)
- interest expense up sharply to $1.4M in the quarter on debt taken for IRRAS acquisition